Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14990625 | 0.88 | GPR119 (0.40) | GPR119SCDSCD5USP30 | |
| SCHEMBL14238800 | 0.87 | SCD (0.47) | GPR119SCDSCD5ACKR3EGLN1 | |
| SCHEMBL15448551 | 0.83 | GPR119 (0.43) | GPR119SCDSCD5USP30ACKR3 | |
| SCHEMBL15436968 | 0.82 | SCD (0.40) | GPR119SCDSCD5USP30ACKR3 | |
| SCHEMBL15437008 | 0.82 | GPR119 (0.39) | GPR119SCDSCD5USP30ACKR3 | |
| SCHEMBL15436975 | 0.82 | GPR119 (0.56) | GPR119 | |
| SCHEMBL15436980 | 0.80 | SCD (0.40) | GPR119SCDSCD5USP30ACKR3 | |
| SCHEMBL15437051 | 0.77 | HSD11B1 (0.40) | GPR119SCDSCD5USP30ACKR3 | |
| SCHEMBL14239729 | 0.75 | GPR119 (0.41) | GPR119ACKR3 | |
| SCHEMBL14240120 | 0.74 | GPR119 (0.40) | GPR119ACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2718288-B1 | SUBSTITUTED PIPERIDINES AS GPR119 MODULATORS FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2015-03-11 | — | — | EP | disclosed |
| US-8921398-B2 | N-cyclopropyl-N-piperidinyl-amide derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-30 | — | — | US | disclosed |
| US-8921398-B2 | N-cyclopropyl-N-piperidinyl-amide derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-30 | — | — | US | disclosed |
| US-20130143892-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130143892-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2012168315-A1 | SUBSTITUTED PIPERIDINES AS GPR119 MODULATORS FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143892-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | GPR119, GPBAR1, TACR1 | GPR119 1/4885SCD 1272/4885SCD5 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.